Protalix BioTherapeutics (NYSE:PLX - Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.05) EPS for the quarter, RTT News reports. Protalix BioTherapeutics had a negative return on equity of 30.89% and a negative net margin of 21.03%.
Protalix BioTherapeutics Trading Down 3.3%
Shares of NYSE:PLX traded down $0.06 during trading on Wednesday, reaching $1.61. The stock had a trading volume of 881,752 shares, compared to its average volume of 523,992. The company has a market capitalization of $127.62 million, a P/E ratio of -12.35 and a beta of -0.05. Protalix BioTherapeutics has a one year low of $0.82 and a one year high of $3.10. The firm's 50-day simple moving average is $2.50 and its 200 day simple moving average is $2.16.
Analyst Upgrades and Downgrades
PLX has been the subject of a number of recent analyst reports. HC Wainwright lifted their price target on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. StockNews.com downgraded Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Monday.
Check Out Our Latest Report on Protalix BioTherapeutics
About Protalix BioTherapeutics
(
Get Free Report)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
Recommended Stories
Before you consider Protalix BioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protalix BioTherapeutics wasn't on the list.
While Protalix BioTherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
